Skip to main content

Table 3 The clinic-pathological parameters among patients with different treatment response and toxicity

From: Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients

Characteristic Response to chemotherapy(N = 90) Toxicity to chemotherapy(N = 211)
Response (N = 29) Non-response (N = 61) p Toxicity (N = 102) No toxicity (N = 109) P
Age in years(mean ± SD) 0.539    0.195
  ≤ 45 4(13.8) 10(16.4)   17(16.7) 22(20.2)  
 46–55 10(34.5) 27(44.3)   39(38.2) 29(26.6)  
  > 55 15(51.7) 24(39.3)   46(45.1) 58(53.2)  
Menstrual status 0.516    0.891
 Premenopausal 8(27.6) 21(34.4)   30(29.4) 33(30.3)  
 Postmenopausal 21(72.4) 40(65.6)   72(70.6) 76(69.7)  
T-status,n(%) 0.250    <0.001*
 T1 / /   / /  
 T2 1(3.4) 5(8.2)   17(16.7) 74(67.9)  
 T3 27(93.1) 56(91.8)   84(82.4) 32(29.4)  
 T4 1(3.4) 0(0)   1(1.0) 3(2.8)  
N-status,n(%) 0.209    0.168
 N0 7(24.1) 27(44.3)   38(37.3) 27(24.8)  
 N1 13(44.8) 23(37.7)   40(39.2) 58(53.2)  
 N2 6(20.7) 9(14.8)   18(17.6) 19(17.4)  
 N3 3(10.3) 2(3.3)   6(5.9) 5(4.6)  
Tumor grade 0.066    0.078
 Grade I / /   / /  
 Grade II 7(24.1) 27(44.3)   41(40.2) 57(52.3)  
 Grade III 22(75.9) 34(55.7)   61(59.8) 52(47.7)  
ER status 0.050    0.650
 Positive 24(82.8) 38(62.3)   72(70.6) 80(73.4)  
 Negative 5(17.2) 23(37.7)   30(29.4) 29(26.6)  
PR status 0.476    0.995
 Positive 24(82.8) 38(62.3)   59(57.8) 63(57.8)  
 Negative 5(17.2) 23(37.7)   43(42.2) 46(42.2)  
Her2 status 0.883    0.525
 Positive 10(34.5) 22(36.1)   35(34.3) 42(38.5)  
 Negative 19(65.5) 39(63.9)   67(65.7) 67(61.5)  
TNBC 0.618    0.428
 yes 2(6.9) 15(24.6)   16(15.7) 13(11.9)  
 no 27(93.1) 46(75.4)   86(84.3) 96(88.1)  
P63 0.967    0.281
 positive 1(3.4) 2(3.3)   3(2.9) 1(0.9)  
 negative 28(96.6) 59(96.7)     
Ki-67 0.324 17(16.7) 22(20.2) 0.195
  < 20% 7(24.1) 21(34.4)   39(38.2) 29(26.6)  
  ≥ 20% 22(75.9) 40(65.6)   46(45.1) 58(53.2)  
  1. T tumor stage, N nodes stage, TNBC triple negative breast cancer, Her 2 human epidermal growth factor receptor 2; * A P value < 0.05 was considered ststistically significant